|
1
|
Laks S, Meyers MO and Kim HJ: Surveillance
for gastric cancer. Surg Clin North Am. 97:317–331. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gill S, Thomas RR and Goldberg RM: Review
article: Colorectal cancer chemotherapy. Aliment Pharmacol Ther.
18:683–692. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu T, Li LF, Shen J, Zhang L and Cho CH:
Chronic inflammation and colorectal cancer: The role of vascular
endothelial growth factor. Curr Pharm Des. 21:2960–2967. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li LF, Chan RL, Lu L, Shen J, Zhang L, Wu
WK, Wang L, Hu T, Li MX and Cho CH: Cigarette smoking and
gastrointestinal diseases: The causal relationship and underlying
molecular mechanisms (Review). Int J Mol Med. 34:372–380. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stein A, Atanackovic D and Bokemeyer C:
Current standards and new trends in the primary treatment of
colorectal cancer. Eur J Cancer. 47 (Suppl 3):S312–S314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miska EA: How microRNAs control cell
division, differentiation and death. Curr Opin Genet Dev.
15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma L and Weinberg RA: Micromanagers of
malignancy: Role of microRNAs in regulating metastasis. Trends
Genet. 24:448–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nelson KM and Weiss GJ: MicroRNAs cancer:
Past, present, and potential future. Mol Cancer Ther. 7:3655–3660.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs-the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheng Y, Yang X, Deng X, Zhang X, Li P,
Tao J and Lu Q: MicroRNA-218 inhibits bladder cancer cell
proliferation, migration, and invasion by targeting BMI-1. Tumor
Biol. 36:8015–8023. 2015. View Article : Google Scholar
|
|
15
|
Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li
DM, Wen YY, Sun HR, Pan MH, Li W, et al: Downregulation of miR-218
contributes to epithelial-mesenchymal transition and tumor
metastasis in lung cancer by targeting Slug/ZEB2 signaling.
Oncogene. 36:2577–2588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sui C, Xu F, Shen W, Geng L, Xie F, Dai B,
Lu J, Zhang M and Yang J: Overexpression of miR-218 inhibits
hepatocellular carcinoma cell growth through RET. Tumor Biol.
36:1511–1518. 2015. View Article : Google Scholar
|
|
17
|
Tang S, Wang D, Zhang Q and Li L: miR-218
suppresses gastric cancer cell proliferation and invasion via
regulation of angiopoietin-2. Exp Ther Med. 12:3837–3842. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uesugi A, Kozaki K, Tsuruta T, Furuta M,
Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive
MicroRNA miR-218 targets the mTOR component rictor and inhibits AKT
phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa M
and Enokida H: MicroRNA-218 inhibits cell migration and invasion in
renal cell carcinoma through targeting caveolin-2 involved in focal
adhesion pathway. J Urol. 190:1059–1068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Safa AR, Day TW and Wu CH: Cellular
FLICE-like inhibitory protein (c-FLIP): A novel target for cancer
therapy. Curr Cancer Drug Targets. 8:37–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Safa AR and Pollok KE: Targeting the
anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel).
3:1639–1671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seo SU, Cho HK, Min KJ, Woo SM, Kim S,
Park JW, Kim SH, Choi YH, Keum YS, Hyun JW, et al: Thioridazine
enhances sensitivity to carboplatin in human head and neck cancer
cells through downregulation of c-FLIP and Mcl-1 expression. Cell
Death Dis. 8:e25992017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yun H, Xie J, Olumi AF, Ghosh R and Kumar
AP: Activation of AKR1C1/ERβ induces apoptosis by downregulation of
c-FLIP in prostate cancer cells: A prospective therapeutic
opportunity. Oncotarget. 6:11600–11613. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang W, Wang S, Song X, Sima N, Xu X, Luo
A, Chen G, Deng D, Xu Q, Meng L, et al: The relationship between
c-FLIP expression and human papillomavirus E2 gene disruption in
cervical carcinogenesis. Gynecol Oncol. 105:571–577. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao L, Yang G, Bai H, Zhang M and Mou D:
NCTD promotes Birinapant-mediated anticancer activity in breast
cancer cells by downregulation of c-FLIP. Oncotarget.
8:26886–26895. 2017.PubMed/NCBI
|
|
27
|
Wright C, Iyer AKV, Yakisich JS and Azad
N: Anti-tumorigenic effects of resveratrol in lung cancer cells
through modulation of c-FLIP. Curr Cancer Drug Targets. 17:669–680.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun J, Luo H, Nie W, Xu X, Miao X, Huang
F, Wu H and Jin X: Protective effect of RIP and c-FLIP in
preventing liver cancer cell apoptosis induced by TRAIL. Int J Clin
Exp Pathol. 8:6519–6525. 2015.PubMed/NCBI
|
|
29
|
Scaffidi C, Schmitz I, Krammer PH and
Peter ME: The role of c-FLIP in modulation of CD95-induced
apoptosis. J Biol Chem. 274:1541–1548. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang G, Fu Y, Liu G, Ye Y and Zhang X:
miR-218 Inhibits proliferation, migration, and EMT of gastric
cancer cells by targeting WASF3. Oncol Res. 25:355–364. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alajez NM, Lenarduzzi M, Ito E, Hui AB,
Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218
suppresses nasopharyngeal cancer progression through downregulation
of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu K, Ding H, Wang W, Liao Z, Fu Z, Hong
Y, Zhou Y, Zhang CY and Chen X: Tumor-suppressive miR-218-5p
inhibits cancer cell proliferation and migration via EGFR in
non-small cell lung cancer. Oncotarget. 7:28075–28085.
2016.PubMed/NCBI
|
|
33
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama
K, Seki N and Nakagawa M: miR-218 on the genomic loss region of
chromosome 4p15.31 functions as a tumor suppressor in bladder
cancer. Int J Oncol. 39:13–21. 2011.PubMed/NCBI
|
|
34
|
Ng EK, Chong WW, Jin H, Lam EK, Shin VY,
Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of
microRNAs in plasma of patients with colorectal cancer: A potential
marker for colorectal cancer screening. Gut. 58:1375–1381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang X, Shi H, Tang H, Fang Z, Wang J and
Cui S: miR-218 inhibits the invasion and migration of colon cancer
cells by targeting the PI3K/Akt/mTOR signaling pathway. Int J Mol
Med. 35:1301–1308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li PL, Zhang X, Wang LL, Du LT, Yang YM,
Li J and Wang CX: MicroRNA-218 is a prognostic indicator in
colorectal cancer and enhances 5-fluorouracil-induced apoptosis by
targeting BIRC5. Carcinogenesis. 36:1484–1493. 2015.PubMed/NCBI
|
|
37
|
He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan
FK, Sung JJ and Yu J: MicroRNA-218 inhibits cell cycle progression
and promotes apoptosis in colon cancer by downregulating BMI1
polycomb ring finger oncogene. Mol Med. 18:1491–1498.
2013.PubMed/NCBI
|
|
38
|
Ilm K, Fuchs S, Mudduluru G and Stein U:
MACC1 is post-transcriptionally regulated by miR-218 in colorectal
cancer. Oncotarget. 7:53443–53458. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Russo A, Saide A, Cagliani R, Cantile M,
Botti G and Russo G: rpL3 promotes the apoptosis of p53 mutated
lung cancer cells by down-regulating CBS and NFκB upon 5-FU
treatment. Sci Rep. 6:383692016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pagliara V, Saide A, Mitidieri E,
d'Emmanuele di Villa Bianca R, Sorrentino R, Russo G and Russo A:
5-FU targets rpL3 to induce mitochondrial apoptosis via
cystathionine-β-synthase in colon cancer cells lacking p53.
Oncotarget. 7:50333–50348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shirley S and Micheau O: Targeting c-FLIP
in cancer. Cancer Lett. 332:141–150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Safa AR: c-FLIP, a master anti-apoptotic
regulator. Exp Oncol. 34:176–184. 2012.PubMed/NCBI
|
|
43
|
Logan IR, McClurg UL, Jones DL, O'Neill
DJ, Shaheen FS, Lunec J, Gaughan L and Robson CN: Nutlin-3 inhibits
androgen receptor-driven c-FLIP expression, resulting in apoptosis
of prostate cancer cells. Oncotarget. 7:74724–74733. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ryang DY, Joo YE, Chung KM, Lim SR, Jeong
HK, Kim HI, Lee WS, Park CH, Kim HS, Choi SK, et al: Expression of
c-FLIP in gastric cancer and its relation to tumor cell
proliferation and apoptosis. Korean J Intern Med. 22:263–269. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zang F, Sun B, Zhao X, Niu R, Zhang S, Yu
M, Wei X and Zhang L: Critical role for c-FLIP(L) on Fas resistance
in colon carcinoma cell line HT-29. Cell Biol Int. 32:329–336.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Galligan L, Longley DB, McEwan M, Wilson
TR, McLaughlin K and Johnston PG: Chemotherapy and TRAIL-mediated
colon cancer cell death: The roles of p53, TRAIL receptors, and
c-FLIP. Mol Cancer Ther. 4:2026–2036. 2005. View Article : Google Scholar : PubMed/NCBI
|
